State Street Corp increased its holdings in shares of Epizyme, Inc. (NASDAQ:EPZM) by 59.6% during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 1,764,450 shares of the biopharmaceutical company’s stock after acquiring an additional 658,727 shares during the period. State Street Corp owned approximately 3.02% of Epizyme worth $26,644,000 as of its most recent SEC filing.
Several other large investors have also bought and sold shares of the company. Palo Alto Investors LLC lifted its stake in Epizyme by 18.9% in the 2nd quarter. Palo Alto Investors LLC now owns 5,698,296 shares of the biopharmaceutical company’s stock valued at $86,044,000 after buying an additional 907,245 shares in the last quarter. Bain Capital Public Equity Management LLC purchased a new position in Epizyme in the 2nd quarter valued at about $4,331,000. Vanguard Group Inc. lifted its stake in Epizyme by 6.2% in the 2nd quarter. Vanguard Group Inc. now owns 3,419,844 shares of the biopharmaceutical company’s stock valued at $51,640,000 after buying an additional 200,982 shares in the last quarter. OxFORD Asset Management LLP purchased a new position in Epizyme in the 2nd quarter valued at about $1,783,000. Finally, Renaissance Technologies LLC purchased a new position in Epizyme in the 1st quarter valued at about $1,975,000. Hedge funds and other institutional investors own 70.95% of the company’s stock.
A number of research analysts recently weighed in on the stock. ValuEngine lowered shares of Epizyme from a “hold” rating to a “sell” rating in a research note on Monday, November 6th. HC Wainwright reaffirmed a “buy” rating and issued a $25.00 price target on shares of Epizyme in a research note on Thursday, November 2nd. Leerink Swann reissued an “outperform” rating and issued a $22.00 target price (down from $28.00) on shares of Epizyme in a research note on Thursday, November 2nd. Royal Bank Of Canada lowered shares of Epizyme from an “outperform” rating to a “sector perform” rating and decreased their target price for the stock from $20.00 to $16.00 in a research note on Thursday, November 2nd. Finally, Cann reissued a “buy” rating and issued a $26.00 target price on shares of Epizyme in a research note on Thursday, November 2nd. One research analyst has rated the stock with a sell rating, two have issued a hold rating and ten have assigned a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $22.67.
In other news, Director David M. Mott purchased 200,000 shares of Epizyme stock in a transaction dated Monday, September 18th. The shares were purchased at an average price of $15.25 per share, with a total value of $3,050,000.00. Following the transaction, the director now owns 6,000 shares in the company, valued at $91,500. The purchase was disclosed in a document filed with the SEC, which is available through this link. Also, insider Peter Tai-Ching Ho sold 15,000 shares of Epizyme stock in a transaction that occurred on Thursday, August 24th. The shares were sold at an average price of $15.68, for a total transaction of $235,200.00. Following the sale, the insider now directly owns 22,228 shares in the company, valued at approximately $348,535.04. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 45,000 shares of company stock worth $733,950. Corporate insiders own 25.20% of the company’s stock.
Epizyme, Inc. (NASDAQ:EPZM) opened at $13.65 on Tuesday. Epizyme, Inc. has a 12 month low of $9.30 and a 12 month high of $20.45.
Epizyme (NASDAQ:EPZM) last released its quarterly earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.63) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.65) by $0.02. equities research analysts anticipate that Epizyme, Inc. will post -2.23 earnings per share for the current fiscal year.
WARNING: This article was first published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this article on another website, it was illegally copied and reposted in violation of U.S. and international trademark & copyright legislation. The correct version of this article can be viewed at https://ledgergazette.com/2017/11/14/state-street-corp-has-26-64-million-stake-in-epizyme-inc-epzm.html.
Epizyme, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company is engaged in the discovery and development of novel epigenetic therapies for cancer patients. The Company develops small molecule inhibitors of a class of enzymes known as histone methyltransferases (HMTs).
Want to see what other hedge funds are holding EPZM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Epizyme, Inc. (NASDAQ:EPZM).
Receive News & Ratings for Epizyme Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme Inc. and related companies with MarketBeat.com's FREE daily email newsletter.